EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded flow of blood, which can have serious consequences in the affected individual. VTE can occur at any age, though it is more common in adults ages 60 years and older and is very rare in children. VTE events are highly dangerous and are associated with high rates of mortality and morbidity.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of VTE in the 8MM, from 1,116,358 cases in 2015 to 1,354,846 in 2025, at an Annual Growth Rate (AGR) of 2.14%. The 8MM had 314,886 diagnosed incident cases of Pulmonary Embolism (PE) in 2015 and GlobalData epidemiologists expect the diagnosed incident cases of PE to increase to 377,612 by 2025, at an AGR of 1.99%. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of Deep Vein Thrombosis (DVT) in the 8MM to increase from 801,472 cases in 2015 to 977,234 cases by 2025, at an AGR of 2.19%. GlobalData epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 8MM from 44,611,144 in 2015 to 54,143,874 in 2025. In addition, GlobalData epidemiologists forecast the number of total knee replacement and revision procedures to grow from 1,532,360 in 2015 to 1,867,289 in 2025. Furthermore, the number of hip replacements is forecast to grow 1,220,965 in 2015 to 1,512,215 in 2025. GlobalData epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.

Scope

The Venous thromboembolism (VTE) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE; the number of VTE attacks; the number of medically ill discharges that are at risk for VTE; the number of primary total knee replacements and revisions; and the number of hip replacements, each segmented by sex and age. Additionally, it includes a forecast for the number of recurrent VTE cases at one and 10 years after incident event, and the number of diagnosed VTE cases with cancer as comorbidity.

The VTE epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Epidemiology

2.1Disease Background

2.2Risk Factors and Comorbidities

2.3Global Trends

2.4Forecast Methodology

2.4.1Sources Used

2.4.2Forecast Assumptions and Methods

2.4.3Sources Not Used

2.5Epidemiological Forecast for VTE (2015–2025)

2.5.1Pulmonary Embolism

2.5.2Deep Vein Thrombosis

2.5.3VTE

2.5.4Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE

2.5.5Number of Primary Total Knee Replacements and Revisions

2.5.6Number of Hip Replacements

2.6Discussion

2.6.1Epidemiological Forecast Insight

2.6.2Limitations of the Analysis

2.6.3Strengths of the Analysis

3Appendix

3.1Bibliography

3.2Physicians and Specialists Included in this Study

3.3About the Authors

3.3.1Epidemiologists

3.3.2Reviewers

3.3.3Global Director of Therapy Analysis and Epidemiology

3.3.4Global Head of Healthcare

3.4About GlobalData

3.5About EpiCast

3.6Contact Us

3.7Disclaimer

Table

Table 1: Risk Factors and Comorbidities for VTE

Table 2: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of PE

Table 3: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of DVT

Table 4: 8MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill

Table 5: 6MM, Sources Used to Forecast Primary Total Knee Replacements

Table 6: 6MM, Sources Used to Forecast the Rate of Primary Total Knee Replacement Requiring Revisions

Table 7: Japan and China, Sources Used to Forecast Primary Total Knee Replacements and Revisions

Table 8: 8MM, Sources Used to Forecast Hip Replacements

Table 9: 8MM, Diagnosed Incident Cases of PE, All Ages, Both Sexes, Select Years 2015–2025

Table 10: 8MM, Diagnosed Incident Cases of DVT, All Ages, Both Sexes, Select Years 2015–2025

Table 11: 8MM, Diagnosed Incident Cases of VTE, All Ages, Both Sexes, Select Years 2015–2025

Table 12: 8MM, Age-Specific Diagnosed Incident Cases of VTE, Both Sexes, N (Row %), 2015

Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of VTE, Both Sexes, N (Row %), 2015

Table 14: 8MM, Number of Recurrent VTE Cases One and 10 Years After Incident VTE Event, Both Sexes, All Ages, N, 2015

Table 15: 8MM, Number of VTE Cases With Cancer Comorbidity, Both Sexes, All Ages, N, 2015 and 2025

Table 16: 8MM, Number of VTE Attacks, Both Sexes, All Ages, N, 2015–2025

Table 17: 8MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Both Sexes, Ages =40 Years, N, 2015

Table 18: 8MM, Number of Primary Total Knee Replacements and Revisions, Both Sexes, Ages =15 Years

Table 19: 8MM, Number of Hip Replacements, Both Sexes, Ages =15 Years

Figures

Figure 1: 8MM, Diagnosed Incident Cases of PE, All Ages, Both Sexes, Select Years 2015–2025

Figure 2: Age-Standardized Diagnosed Incidence of PE, All Ages, Cases Per 100,000, 2015

Figure 3: 8MM, Diagnosed Incident Cases of DVT, All Ages, Both Sexes, Select Years 2015–2025

Figure 4: Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases Per 100,000 Population, 2015

Figure 5: 8MM, Diagnosed Incident Cases of VTE, All Ages, Both Sexes, Select Years 2015–2025

Figure 6: 8MM, Age-Specific Diagnosed Incident Cases of VTE, Both Sexes, N (Row %), 2015

Figure 7: 8MM, Sex-Specific Diagnosed Incident Cases of VTE, Both Sexes, N, 2015

Figure 8: 8MM, Number of VTE Attacks, Both Sexes, All Ages, N, 2015–2025

Figure 9: 8MM, Number of Primary Total Knee Replacements and Revisions, Both Sexes, Ages =15 Years

Figure 10: 8MM, Number Hip Replacements, Both Sexes, Ages =15 Years

Frequently asked questions

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2025 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.